Carcinogenicity of some aromatic amines, organic dyes, and related exposuresA review of human carcinogens - Part F: chemical agents and related occupationsCarcinogenicity of trichloroethylene, tetrachloroethylene, some other chlorinated solvents, and their metabolitesCarcinogenicity of polychlorinated biphenyls and polybrominated biphenylsCarcinogenicity of fluoro-edenite, silicon carbide fibres and whiskers, and carbon nanotubesEfficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III studyPrognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trialAssociation between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studiesPeriodontal disease, tooth loss, and cancer risk in male health professionals: a prospective cohort studyA subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification studyNew-onset diabetes: a potential clue to the early diagnosis of pancreatic cancerAddition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data.Establishment of a cancer surveillance programme: the South African experienceTransformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of originNomograms in oncology: more than meets the eyePharmacogenetic biomarkers for the prediction of response to antiangiogenic treatmentEpidemiology, biology, and treatment of triple-negative breast cancer in women of African ancestryExtracranial rhabdoid tumours: what we have learned so far and future directionsSafety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label studyEffects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer.Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysisEGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study.Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial.Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial.Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation.MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study.Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study.CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study.Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial.Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial.Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study.The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials.Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial
P1433
Q24170366-2ADBEAEF-3F50-4136-BD71-8C2F0D65E104Q24170367-2BEF62FA-42A4-4F1B-90DD-3431CE65DA06Q24170368-CAFA12E6-C5E5-4265-8B06-889857519670Q24170369-ADD82A21-378A-4E13-B92D-9DFB10B50F67Q24170370-755A9E14-1B41-4686-BA54-2442F75BC9F8Q24563021-48AF2793-7531-4603-A74A-1F1C89D8F64CQ24597456-939768EC-CF4A-42CB-A9A7-34690CA5F5AAQ24619808-8B93FDDA-9601-41DD-A5E2-603C4CC15D91Q24645966-9C16603E-1BE7-4E22-A039-6F57658B0A22Q24651897-DA05A01D-F2DB-4042-B7AB-9DC7E2D1E1C3Q24656132-F4DFB8CF-7291-4EBF-8B78-E304E898E912Q26771537-5FC6B800-8C22-4E20-ADB9-8C211DA90A2FQ26801405-666B4B78-8DB3-4E8F-BA47-62D7F7888F4AQ26826437-205007E1-C5DF-40A1-B2D4-A7E95A39BDAFQ26830260-46637459-227F-4C4D-AF9F-AC4B88704160Q26996793-1DDF4088-02D7-46E6-A726-DDD2F0B22CEFQ27011535-555045B0-270B-43B2-8318-E64FF065EB47Q27027021-5618101B-D8D3-4E86-8D19-2F8C4704C190Q27276774-D569DA9E-14F0-4C9E-A2D7-7688E380B236Q27851573-97777EEE-11CD-48DF-BFBD-AB361551F47BQ27851616-EADB4AE7-8641-4342-B424-82B2F575E121Q27851671-C44CC00F-8AD9-4A0D-9824-B4A8C5C2E565Q27851683-E13B8463-63F6-486D-8AC4-6423053A03A5Q27851712-B19610FE-D3C2-4EA3-A0C5-FD335294F5DFQ27851751-51259008-7702-4FA0-845F-5C691E031DDEQ27851852-E3D77CB4-5500-405E-9840-AA8A96DE08CFQ27851856-8337ED1C-E131-4A77-97BE-33E8706544B0Q27851971-47D95C3F-D3D1-499A-94EF-D71AE71DC76FQ27852038-381F8AEF-BB6B-4189-9670-4062AF8983BAQ27852083-476BD8B1-A17F-4A48-A3A2-6A09B8E160EBQ27852211-97FD9D95-FE8D-4C37-B3C7-A67A4B57AA50Q27852261-2BA73FBE-B143-4A75-ADBF-7BC373C60D75Q27852333-3CAAE2B7-D414-44A0-89DA-83EE616F0588Q27852787-3B5BC379-3FAD-4B07-9E73-6260E0CF9588Q27853001-7A8503F2-1673-4433-BCEA-937F2F92CE6AQ27853059-320FF0D5-0DCA-45E4-9CCC-192BC0498AEAQ27853070-829630C1-ADA5-404A-A262-F6F5B54B3F09Q27853110-909213C1-AB86-4059-A256-04398AECB13DQ27853120-A75872D4-33A1-4824-8EB1-16483B6D8FB0Q27853153-6109C781-BA6E-44A1-BD35-9CD3775B7701
P1433
description
begutachtete wissenschaftliche Zeitschrift
@de
peer-reviewed scientific journal
@en
periodiek van uitgeverij Elsevier
@nl
revista científica
@es
rivista scientifica
@it
рецензований науковий журнал
@uk
वैज्ञानिक पत्रिका
@hi
name
Lancet Oncology
@nl
The Lancet Oncology
@da
The Lancet Oncology
@de
The Lancet Oncology
@en
The Lancet Oncology
@es
The Lancet Oncology
@fi
The Lancet Oncology
@fr
The Lancet Oncology
@it
The Lancet Oncology
@nb
The Lancet Oncology
@nn
type
label
Lancet Oncology
@nl
The Lancet Oncology
@da
The Lancet Oncology
@de
The Lancet Oncology
@en
The Lancet Oncology
@es
The Lancet Oncology
@fi
The Lancet Oncology
@fr
The Lancet Oncology
@it
The Lancet Oncology
@nb
The Lancet Oncology
@nn
altLabel
Lancet Oncology
@en
prefLabel
Lancet Oncology
@nl
The Lancet Oncology
@da
The Lancet Oncology
@de
The Lancet Oncology
@en
The Lancet Oncology
@es
The Lancet Oncology
@fi
The Lancet Oncology
@fr
The Lancet Oncology
@it
The Lancet Oncology
@nb
The Lancet Oncology
@nn
P3181
P1055
P1058
P1156
P123
P1250
P1277
P1476
The Lancet Oncology
@en
P236
P571
2000-01-01T00:00:00Z